TORONTO – Apotex Inc. announced its CEO, Allan Oberman, is stepping down effective immediately.
The Toronto-based drug company says he will be succeeded by Jeff Watson, who previously served as the CEO from 2018 to 2023.
Aaron Davenport, the chairman of Apotex’s board, says Watson’s track record of delivering results and his commitment to patient access and innovation make him an ideal leader for the company.
He also says Oberman’s industry expertise and leadership have been instrumental in shaping the strategic direction of the company.
Apotex says Oberman, who has acted as president and CEO since 2023, will resume his role as a member of the board as part of the transition.
The leadership change comes after Apotex moved in February to acquire CanPrev, a Canadian provider of vitamins, supplements and other natural health products.
This report by The Canadian Press was first published March 30, 2026.
